From Yahoo Finance: 2025-05-11 17:21:00

Akero Therapeutics, Inc. (AKRO) is among the top healthcare stocks to buy now. President Trump’s executive order seeks to allow Medicare to negotiate drug prices, benefiting the sector. Drug makers are also pushing for longer timelines for price negotiations. The order aims to cut healthcare costs and may lead to sector-specific tariffs.

Medicare’s negotiation powers are contentious, especially regarding drug innovation. The Trump administration plans to negotiate prices for 15 medications, including cancer and diabetes drugs. Akero Therapeutics, Inc. (AKRO) is a clinical-stage company developing treatments for metabolic diseases. Analysts maintain a positive outlook on AKRO, citing its potential for success in phase 3 trials.

AKRO ranks 6th among the best performing healthcare stocks. While AKRO shows promise, some AI stocks may offer higher returns in a shorter timeframe. Investors interested in AI stocks can explore other options. Analysts believe AKRO’s sole clinical asset, Efruxifermin, holds significant potential for treating metabolic diseases. Cheaper AI stocks may present better investment opportunities than AKRO.



Read more at Yahoo Finance: Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now